Patents by Inventor Dominique-Charles Valla

Dominique-Charles Valla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and kits for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension
    Patent number: 9494599
    Abstract: The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41?), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.
    Type: Grant
    Filed: January 28, 2013
    Date of Patent: November 15, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DIDEROT (PARIS VII), UNIVERSITE DE VERSAILLES SAINT-QUENTIN-EN-YVELINES, UNIVERSITE PARIS DESCARTES, ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS
    Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger, Dominique-Charles Valla
  • METHODS AND KITS FOR DETERMINING WHETHER A PATIENT WITH CIRRHOSIS IS AT RISK OF HAVING CLINICALLY SIGNIFICANT PORTAL HYPERTENSION
    Publication number: 20150168426
    Abstract: The present invention relates to a method for determining whether a patient with cirrhosis is at risk of having clinically significant portal hypertension comprising the steps consisting of i) quantifying the levels of leuko-endothelial (CD31+/41?), pan-leukocyte (CD11a+), lymphocyte (CD4+), erythrocyte (CD235a+) and hepatocyte-derived (cytokeratin-18+) microparticles in a blood sample obtained from the patient and ii) comparing said levels with predetermined reference values wherein a difference between the levels quantified at step i) and the predetermined reference values is indicative whether the patient is at risk of having clinically significant portal hypertension.
    Type: Application
    Filed: January 28, 2013
    Publication date: June 18, 2015
    Inventors: Pierre-Emmanuel Rautou, Chantal Boulanger, Dominique-Charles Valla